Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
المؤلفون المشاركون
Enlund, F.
Holmberg, E.
Andersson, C.
Nyman, J.
Sjögren, H.
Hussein, A.
Hallqvist, A.
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-09-17
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations.
We wanted to explore the prognostic impact of mutated KRAS in the stage III setting treated with high-dose radiochemotherapy.
Methods.
Samples were obtained from patients participating in two prospective studies of locally advanced NSCLC receiving combined radiochemotherapy: the RAKET study, a randomized phase II study where patients were treated with induction chemotherapy (carboplatin/paclitaxel) followed by concurrent radiochemotherapy, and the Satellite trial, a phase II study with induction chemotherapy (cisplatin/docetaxel) followed by radiotherapy concurrent cetuximab.
The samples were analysed regarding KRAS mutations, EGFR mutations, and EGFR FISH positivity.
Results.
Patients with mutated KRAS had a significantly inferior survival, which maintained its significance in a multivariate analysis when other possible prognostic factors were taken into account.
The prevalence of KRAS mutations, EGFR mutations, and EGFR FISH positivity were 28.8%, 7.5%, and 19.7%, respectively.
Conclusion.
Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined radiochemotherapy.
The prevalence of KRAS mutations and EGFR mutations are as expected in this Scandinavian population.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hallqvist, A.& Enlund, F.& Andersson, C.& Sjögren, H.& Hussein, A.& Holmberg, E.…[et al.]. 2012. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-483043
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hallqvist, A.…[et al.]. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-483043
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hallqvist, A.& Enlund, F.& Andersson, C.& Sjögren, H.& Hussein, A.& Holmberg, E.…[et al.]. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-483043
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-483043
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر